Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: Rationale and design of the MAGIC study

Cardiovascular Drugs and Therapy

Volumn 25, Issue 6, 2011, Pages 551-560

  Origasa, Hideki ^a   Goto, Shinya ^b   Shimada, Kazuyuki ^c   Uchiyama, Shinichiro ^d   Okada, Yasushi ^e   Sugano, Kentaro ^c   Hiraishi, Hideyuki ^f   Uemura, Naomi ^g   Ikeda, Yasuo ^h  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h WASEDA UNIVERSITY   (Japan)

Author keywords

Cerebrovascular diseases; Cohort studies; Coronary artery diseases; Gastrointestinal complications; Low dose aspirin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; CORTICOSTEROID; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETODOLAC; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOXOPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; TICLOPIDINE;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM ULCER; DISEASE DURATION; ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STOMACH EROSION; VASCULAR DISEASE;

ASPIRIN; COHORT STUDIES; EPIDEMIOLOGIC RESEARCH DESIGN; GASTROINTESTINAL DISEASES; HUMANS; JAPAN; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; VASCULAR DISEASES;

EID: 83055172961     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6328-2     Document Type: Article

References (45)

1. GK Hansson 2005 Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 1685 95 15843671 1:CAS:528:DC%2BD2MXjsFCltrc%3D
2. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients BMJ 324 71 86
3. C Patrono A Luis LA García Rodríguez R Landolfi C Baigent 2005 Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2373 83 16319386 1:CAS:528:DC%2BD2MXht1OmsbnM (Pubitemid 41713749)
4. SM Weisman DY Graham 2002 Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events Arch Intern Med 162 2197 202 12390062 1:CAS:528:DC%2BD38XovVWjur4%3D (Pubitemid 35231588)
5. RS Eidelman PR Hebert SM Weisman CH Hennekens 2003 An update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 163 2006 10 14504112 (Pubitemid 37151241)
6. JE Dalen 2006 Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 119 198 202 16490462 1:CAS:528:DC%2BD28XhsFGgsLk%3D (Pubitemid 43255057)
7. Antithorombotic Trialists' (ATT) Collaboration 2009 Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 1849 60
8. TA Pearson SN Blair SR Daniels RH Eckel JM Fair SP Fortmann, et al. 2002 AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 106 388 91 12119259 (Pubitemid 34778969)
9. L Mosca CL Banka EJ Benjamin K Berra C Bushnell RJ Dolor, et al. 2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update Circulation 115 1481 501 17309915 (Pubitemid 46648385)
10. M Hayden M Pignone C Phillips C Mulrow 2002 Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 136 161 72 11790072 1:CAS:528:DC%2BD38XnsVamsQ%3D%3D (Pubitemid 34073943)
11. MM Wolfe DR Lichtenstein G Singh 1999 Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1888 99 10369853 1:CAS:528:DyaK1MXktFKrtbs%3D (Pubitemid 29272670)
12. LA García Rodríguez S Hernández-Díaz FJ de Abajo 2001 Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Br J Clin Pharmacol 52 563 71 11736865
13. C Sakamoto K Sugano S Ota N Sakaki S Takahashi Y Yoshida, et al. 2006 Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan Eur J Clin Pharmacol 62 765 72 16821007 1:CAS:528:DC%2BD28XotlChtrc%3D (Pubitemid 44289508)
14. K Barada W Karrowni M Abdallah W Shamseddeen AI Sharara HA Dakik 2008 Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors J Clin Gastroenterol 42 368 72 18277903 1:CAS:528:DC%2BD1cXjsFWltbw%3D (Pubitemid 351450621)
15. H Sato K Ishikawa A Kitabatake S Ogawa Y Maruyama Y Yokota, et al. 2006 Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial Stroke 37 447 51 16385088 1:CAS:528:DC%2BD28XlvVCntg%3D%3D (Pubitemid 43732003)
16. H Ogawa M Nakayama T Morimoto S Uemura M Kanauchi N Doi, et al. 2008 Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2134 41 18997198 1:CAS:528:DC%2BD1cXhtlOrtLnM
17. A Lanas A Ferrández 2002 Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding Expert Opin Drug Saf 1 245 52 12904140 1:CAS:528:DC%2BD38XotlOjt7c%3D
18. FL Lanza 1998 A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology Am J Gastroenterol 93 2037 46 9820370 1:CAS:528:DyaK1cXnsFGns7o%3D
19. ND Yeomans AI Lanas NJ Talley AB Thompson R Daneshojoo B Eriksson, et al. 2005 Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin Aliment Pharmacol Ther 22 795 801 16225488 1:STN:280:DC%2BD2MrkvFWruw%3D%3D (Pubitemid 41564359)
20. JQ Huang S Sridhar RH Hunt 2002 Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis Lancet 359 14 22 11809181 1:CAS:528:DC%2BD38XmsV2msQ%3D%3D (Pubitemid 34119190)
21. S Suerbaum P Michetti 2002 Helicobacter pylori infection N Engl J Med 347 1175 86 12374879 1:CAS:528:DC%2BD38XnslShsbo%3D
22. T Chiba H Seno H Marusawa Y Wakatsuki K Okazaki 2006 Host factors are important in determining clinical outcomes of Helicobacter pylori infection J Gastroenterol 41 1 9 16501851
23. T Morimoto M Nakayama Y Saito H Ogawa 2007 Aspirin for primary prevention of atherosclerotic disease in Japan J Atheroscler Thromb 14 159 66 17726295 1:CAS:528:DC%2BD2sXhtFantbvI
24. CJ Hawkey JA Karrasch L Szczepañski DG Walker A Barkun AJ Swannell, et al. 1998 Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group N Engl J Med 338 727 34 9494149 1:CAS:528:DyaK1cXitFars7w%3D (Pubitemid 28115091)
25. ND Yeomans Z Tulassay L Juhász I Rácz JM Howard CJ van Rensburg, et al. 1998 A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group N Engl J Med 338 719 26 9494148 1:CAS:528:DyaK1cXitFars78%3D
26. KC Lai SK Lam KM Chu BC Wong WM Hui WH Hu, et al. 2002 Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 346 2033 8 12087138 1:CAS:528:DC%2BD38XkvFartb4%3D (Pubitemid 34680594)
27. FK Chan VW Wong BY Suen JC Wu JY Ching LC Hung, et al. 2007 Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial Lancet 369 1621 6 17499604 1:CAS:528:DC%2BD2sXltF2qsrY%3D (Pubitemid 46710125)
28. AS Taha C McCloskey R Prasad V Bezlyak 2009 Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial Lancet 374 119 25 19577798 1:CAS:528:DC%2BD1MXotl2ks7o%3D
29. Working group of developing a guideline for gastric ulcer in Japan. Guideline for clinical practice of gastric ulcer based on EBM, 2nd edn (in Japanese). Jiho, Tokyo, 2007. pp. 101-110.
30. DL Bhatt J Scheiman NS Abraham EM Antman FK Chan CD Furberg, et al. 2008 ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 52 1502 17 19017521
31. Y Naito T Yoshikawa S Iimura N Yagi K Matsuyama Y Boku, et al. 1998 Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study Dig Dis Sci 43 83S 9 9753232 1:CAS:528:DyaK1cXmsV2rsL0%3D
32. TA Stukel ES Fisher DE Wennberg DA Alter DJ Gottlieb MJ Vermeulen 2007 Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods JAMA 297 278 85 17227979 1:CAS:528: DC%2BD2sXotVCmuw%3D%3D (Pubitemid 46143305)
33. RB D'Agostino Jr RB D'Agostino Sr 2007 Estimating treatment effects using observational data JAMA 297 314 6 17227985 (Pubitemid 46143312)
34. JS Berger MJ Krantz JM Kittelson WR Hiatt 2009 Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials JAMA 301 1909 19 19436018 1:CAS:528:DC%2BD1MXlslKms78%3D
35. J Weil D Colin-Jones M Langman D Lawson R Logan M Murphy, et al. 1995 Prophylactic aspirin and risk of peptic ulcer bleeding BMJ 310 827 30 7711618 1:STN:280:DyaK2M3islSntg%3D%3D
36. HT Sørensen L Mellemkjaer WJ Blot GL Nielsen FH Steffensen JK McLaughlin, et al. 2000 Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin Am J Gastroenterol 95 2218 24 11007221
37. A Lanas LA García-Rodríguez MT Arroyo F Gomollón F Feu A González-Pérez, et al. 2006 Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations Gut 55 1731 8 16687434 1:CAS:528:DC%2BD2sXkvFKqsQ%3D%3D (Pubitemid 44893570)
38. JP Kelly DW Kaufman JM Jurgelon J Sheehan RS Koff S Shapiro 1996 Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product Lancet 348 1413 6 8937281 1:STN:280:DyaK2s%2FptFKitg%3D%3D (Pubitemid 26395236)
39. M Asaka K Satoh K Sugano T Sugiyama S Takahashi Y Fukuda, et al. 2001 Guidelines in the management of Helicobacter pylori infection in Japan Helicobacter 6 177 86 11683920 1:STN:280:DC%2BD3MnjsFalsA%3D%3D (Pubitemid 32843601)
40. N Uemura S Okasato S Yamamoto N Matsubara S Yamaguchi M Yamakido, et al. 2001 Helicobacter pylori infection and the development of gastric cancer N Engl J Med 345 784 9 11556297 1:STN:280:DC%2BD3MrgslCqtA%3D%3D
41. PJ Hu YY Li MH Zhou MH Chen GG Du BJ Huang, et al. 1995 Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and a low prevalence of gastric cancer in a developing nation Gut 36 198 202 7883217 1:STN:280:DyaK2M7ovFWgtw%3D%3D
42. GK Kitchingman PJ Prichard TK Daneshmend RP Walt CJ Hawkey 1989 Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine Br J Clin Pharmacol 28 581 5 2590612 1:CAS:528:DyaK3cXjtVCmtA%3D%3D (Pubitemid 19273606)
43. A Shiotani T Sakakibara Y Yamanaka H Imamura K Tarumi N Manabe, et al. 2009 Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin J Gastroenterol 44 126 31 19214674 1:CAS:528:DC%2BD1MXhvVyqsb4%3D
44. M Gilard B Arnaud JC Cornily G Le Gal K Lacut G Le Calvez, et al. 2008 Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 256 60 18206732 1:CAS:528:DC%2BD1cXpt1Gksg%3D%3D
45. HD Aronow SR Steinhubl DM Brennan PB Berger EJ Topol 2009 Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 157 369 74 19185647 1:CAS:528: DC%2BD1MXhtlSkt70%3D